Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, TDS

New Intelligence Tool Helps Researchers Cope With Immuno-Oncology Boom


LONDON, Nov. 23, 2017 /PRNewswire/ -- Hanson Wade, the London-based life sciences knowledge services specialist, has launched IO Combination Trials Intelligence (www.beacon-intelligence.com), to provide clarity to scientists and strategists in the booming immuno-oncology combination field of study.

IO Combination Trials Intelligence is part of Hanson Wade's Beacon Targeted Therapies service. It specializes in curating data and intelligence in targeted therapies and targeted therapies alone. Using a team of scientists, they are able to standardize, classify and clarify data to support drug development decision making.

"Our in-depth market research showed that scientists, strategists and investors are struggling to cope with the scale and pace of development in this sector," said Andy Cook, Director of Digital Products, Hanson Wade. "In the past 12 months alone, more than 800 new IO combination trials have been initiated. We are also seeing hundreds of trial updates per month. It is no surprise that drug developers are struggling to gather signal from noise."

IO Combination Trials Intelligence researchers curate data from the widest range of sources including trial registries, academic papers, company presentations, conferences and much, much more. They standardize findings and remove ambiguities.

Early adopters of the service have been able to improve the confidence and efficiency of their intelligence gathering, as the data set removes the need for users to weed out false positives.

The service was unveiled on the 15th of November at the ICI Europe Conference in Munich.

The IO Combination Data Intelligence products will be augmented by the launch of an Immune Checkpoint Monotherapies Intelligence service later this year.

Media Contact:
Andy Cook
+44 203 141 8700

Related Images

image1.png
Beacon IO Combination Trials Intelligence

image2.png
Beacon IO Combination Trials Intelligence

image3.png
Beacon IO Combination Trials Intelligence

image4.png
Beacon IO Combination Trials Intelligence

Related Links

Beacon Intelligence

SOURCE Hanson Wade


These press releases may also interest you

at 09:38
The Wyatt Foundation and The Conceive Fertility Foundation announce today a joint partnership that will award $15,000 grants to five individuals/couples who need in vitro fertility (IVF) to build their families. Launching during National Infertility...

at 09:38
New platform and surgery center investment adds advanced facility capabilities to specialty care network, strengthening in-person treatment and attracting leading orthopedic surgeons and physiciansWith Theater launch, value-based MSK care visionary...

at 09:34
The below resolutions were passed at Medicover's annual general meeting (the "AGM") held today on 26 April 2024. Election of the board of directors and auditor The AGM resolved, in accordance with the proposal from the nomination committee, that the...

at 09:00
Dental Care Acworth is thrilled to utilize this remarkable innovation and offer patients unbiased, objective and standardized dental care that they know they can trust. The AI solutions Pearl delivers can assist dental...

at 09:00
Tolland Hill Family Dental is thrilled to announce the addition of Dr. Conway Ma to its esteemed team of dental professionals. Tolland Hill Family Dental offers a wide range of services, catering to patients of all ages. From a child's first dental...

at 09:00
Amgen today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1...



News published on and distributed by: